Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inviragen has announced that it will receive a financial grant from the pediatric dengue vaccine initiative to manufacture dengue vaccine in preparation for testing in human clinical trials.
Subscribe to our email newsletter
Inviragen’s dengue vaccine was designed by collaborators at the Centers for Disease Control and Prevention in Fort Collins, Colorado to protect against all four of the dengue viruses. The vaccine has been shown to be safe and effective in preclinical animal models. Inviragen intends to begin human clinical testing of its vaccine in the second half of 2008.
Dan Stinchcomb, CEO of Inviragen, said: “This financial support from pediatric dengue vaccine initiative (PDVI) will accelerate the development of our dengue vaccine. We decided early on to partner with one of the leading vaccine manufacturers in India, Shantha Biotechnics, for the manufacture of our vaccine for human clinical trials. The grant from PDVI validates our strategy and will partially support our vaccine manufacturing efforts at Shantha.”
Harold Margolis, director of the PDVI, said: “PDVI is supporting a number of potential vaccines for the prevention of dengue and Inviragen’s vaccine is a key component of our portfolio. Our support of the Inviragen/Shantha collaboration helps to assure that this dengue vaccine could be manufactured cost-effectively in the developing world.”